This is an expected clinical milestone with no efficacy data — no immediate trading catalyst. Monitor for initial clinical data readout later this year, which will be the key value inflection point for RV-01.
Price Chart
Executive Summary
Radiopharm Theranostics dosed the first patient in the second cohort (70 mCi dose) of its Phase 1/2a trial for RV-01 (BetaBart), a 177Lu-labeled antibody targeting B7-H3 in solid tumors, following a positive Safety Monitoring Committee recommendation. This is a routine clinical milestone for a pre-revenue biotech — the trial is still in early dose escalation with no efficacy data yet. The filing is neutral; the event is expected and does not change the risk/reward profile of the stock.
Key Facts
- Dosed first patient in second cohort (70 mCi) of Phase 1/2a trial for RV-01 (177Lu-Betabart) targeting B7-H3 expressing solid tumors.
- Safety Monitoring Committee recommended dose escalation to 70 mCi after first cohort.
- Trial (NCT07189871) is a FIH dose escalation/expansion study enrolling up to 61 patients across multiple solid tumor types.
- RV-01 is the first therapeutic radiopharmaceutical from the joint venture with MD Anderson Cancer Center.
- No financial data, revenue, or guidance provided in the filing.
Financial Impact
No financial figures reported; pre-revenue clinical-stage company.
Risk Factors
- Phase 1/2a dose escalation trials have high failure rates; no efficacy data yet.
- Pre-revenue biotech with no approved products; dependent on future financing for operations.
- Small market cap ($36M) amplifies binary risk around clinical data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-093730 |
| Document: 0001213900-26-093730-index-headers.html | 0001213900-26-093730 |
| Document: 0001213900-26-093730-index.html | 0001213900-26-093730 |
| Document: 0001213900-26-093730.txt | 0001213900-26-093730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9000 (−6.25%) |
Oct 26, 2026 1d ago | 6-K | $0.9960 | awaiting T+5 | — | $0.9000 (−9.64%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.9000 (−9.09%) |
Oct 14, 2026 12d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9000 (−16.67%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9000 (−29.13%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9000 (−39.19%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9000 (−44.44%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9000 (+42.74%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9000 (−45.45%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9000 (−55.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers